<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756208</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00065547</org_study_id>
    <nct_id>NCT02756208</nct_id>
  </id_info>
  <brief_title>A Safety and Immunogenicity Trial of IHV01</brief_title>
  <acronym>FLSC-001</acronym>
  <official_title>A Phase I Safety and Immunogenicity Trial of IHV01 in HIV-1 Uninfected Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auro Vaccines LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized,&#xD;
      placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult&#xD;
      volunteers (Human Immunodeficiency Virus-1 uninfected).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 randomized, placebo-controlled, modified double-blinded dose escalation&#xD;
      study in 60 healthy adult volunteers who are Human Immunodeficiency Virus-1 (HIV-1)&#xD;
      uninfected. Participants in the study will receive 4 injections at 0, 4, 8 and 24 weeks and&#xD;
      will be followed for an additional 24 weeks. The total study duration will be 48 weeks. As&#xD;
      this is a Phase 1 trial, the primary objective is to document safety of the Full Length&#xD;
      Single Chain (FLSC) gp120-CD4 complex vaccine with a secondary objective to evaluate immune&#xD;
      responses induced by the vaccine. This vaccine is being evaluated as it is constructed so&#xD;
      that the gp120 and CD4 moieties form a stable intra-chain binding interaction that forms a&#xD;
      transition state structure that presents conserved, conformational domains involved in the&#xD;
      early HIV replication process. It is hypothesized that antibodies directed to these epitopes&#xD;
      would be highly cross-reactive and potentially useful for HIV vaccine development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Local and Systemic Reactogenicity Signs and Symptoms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Signs and symptoms include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Related Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Treatment emergent adverse events assessed by investigator to be either possibly, probably, or definitely related to study treatment. Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Sustained Decrease in CD4 Count and CD4%.</measure>
    <time_frame>48 weeks</time_frame>
    <description>CD4 count was monitored from baseline and at each study visit through study completion. Baseline CD4 and CD4% levels were calculated by taking the average of the screening and first vaccination visits. The number of individuals who had sustained (2 consecutive time points) 30% decrease in CD4 cell/ul and CD4% from baseline were counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binding Antibody Response Rates to FLSC</measure>
    <time_frame>2 weeks after 4th (last) vaccination.</time_frame>
    <description>Percent of participants with anti-FLSC antibodies as assessed by ELISA by 2 weeks after final vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding Antibody Response Rates to BaL-gp120</measure>
    <time_frame>2 weeks after 4th (last) vaccination</time_frame>
    <description>Percent of participants with anti-gp120 antibodies as assessed by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Competitive Antibody Rates to CD4i Epitopes</measure>
    <time_frame>2 weeks after 4th (last) vaccination</time_frame>
    <description>Percent of participants with antibodies competing with A32 or 17b as assessed by ELISA.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>300 ug FLSC vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be vaccinated with 300 ug FLSC vaccine (highest vaccine dose) on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 ug FLSC vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be vaccinated with 150 ug FLSC vaccine (middle vaccine dose) on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 ug FLSC vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be vaccinated with 75 ug FLSC vaccine (lowest vaccine dose) on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be vaccinated with placebo (control group) on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>300 ug FLSC vaccine</intervention_name>
    <description>FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>300 ug FLSC vaccine</arm_group_label>
    <other_name>Full length single chain gp120-CD4 complex vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>150 ug FLSC vaccine</intervention_name>
    <description>FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>150 ug FLSC vaccine</arm_group_label>
    <other_name>Full length single chain gp120-CD4 complex vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>75 ug FLSC vaccine</intervention_name>
    <description>FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>75 ug FLSC vaccine</arm_group_label>
    <other_name>Full length single chain gp120-CD4 complex vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sterile saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 to 45 years of age.&#xD;
&#xD;
          2. Sex: Male or Female (female volunteers of child bearing potential must have a negative&#xD;
             serum beta human chorionic gonadotropin (b-HCG or pregnancy) test at time of screening&#xD;
             and entry into the study and provide assurance of the use of effective(as judged by&#xD;
             the investigator) birth control methods or abstinence beginning at least 60 days prior&#xD;
             to the study and during the study&#xD;
&#xD;
          3. Documented HIV-1 negative by ELISA&#xD;
&#xD;
          4. Be in good general health without clinically significant medical history, physical&#xD;
             examination findings, or clinically significant abnormal laboratory results (i.e.,&#xD;
             chronic medical conditions as noted in the exclusion criteria such as cancer as well&#xD;
             as any conditions that in the opinion of the investigator might pose a risk to the&#xD;
             volunteer)&#xD;
&#xD;
          5. No identifiable risk factor for acquisition of HIV infection (i.e., intravenous drug&#xD;
             use/needle sharing, unprotected sex with multiple partners)&#xD;
&#xD;
          6. Negative b-HCG pregnancy test on the day of initial vaccination.&#xD;
&#xD;
          7. Negative screen for Hepatitis B surface antigen (HBsAg);&#xD;
&#xD;
          8. Negative screen for antibodies to Hepatitis C virus (Patient may enroll if patient can&#xD;
             provide documentation of negative hepatitis C viral load.)&#xD;
&#xD;
          9. Participant must have a CD4 count ( a type of white blood cells) within the normal&#xD;
             range of the clinical laboratory utilized for the study and a CD4 percentage within&#xD;
             20% of the normal range of the clinical laboratory&#xD;
&#xD;
         10. Laboratory parameters must be within pre-specified limits as defined by exclusion&#xD;
             criteria.&#xD;
&#xD;
         11. Volunteers must be willing and able to provide written informed consent to participate&#xD;
             in the study.&#xD;
&#xD;
         12. Available for at least 48 weeks of follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. High risk behavior for acquisition of HIV within 24 weeks of study entry(i.e.,&#xD;
             intravenous drug use/needle sharing, unprotected sex with multiple partners)&#xD;
&#xD;
          2. Volunteers with an acute and clinically significant medical event (as determined by&#xD;
             the investigator) within the past 30 days of screening.&#xD;
&#xD;
          3. Have active tuberculosis or other systemic infectious process by review of systems and&#xD;
             physical examination&#xD;
&#xD;
          4. Have a history of immunodeficiency, autoimmune disease, or use of immunosuppressive&#xD;
             medications&#xD;
&#xD;
          5. Current treatment for malignancy other than basal or squamous cell carcinoma of the&#xD;
             skin or carcinoma in situ of the cervix&#xD;
&#xD;
          6. Is pregnant&#xD;
&#xD;
          7. History of any chronic illness that would interfere with conduct or completion of&#xD;
             study(as determined by the investigator)&#xD;
&#xD;
          8. Have evidence of psychiatric, medical and/or substance abuse problems during the past&#xD;
             24 weeks that the investigator believes would adversely affect the volunteer's ability&#xD;
             to participate in the trial&#xD;
&#xD;
          9. Have occupational or other responsibilities that would prevent completion of&#xD;
             participation in the study&#xD;
&#xD;
         10. Have received any live, attenuated vaccine except rabies vaccine within 60 days of&#xD;
             study entry&#xD;
&#xD;
         11. Vaccine (FDA approved; e.g. influenza, pneumovax, etc) administration within 30 days&#xD;
             of immunization with the study vaccine. NOTE: Medically indicated subunit or killed&#xD;
             vaccines (e.g., Hepatitis A or Hepatitis B) should be given prior to trial initiation&#xD;
             or after completion of the study immunizations. If patient requires immunization,&#xD;
             injections should be given more than 2 weeks prior or 2 weeks after study immunization&#xD;
&#xD;
         12. Have used experimental therapeutic agents within 30 days of study entry&#xD;
&#xD;
         13. Have received blood products or immunoglobulins in the past 12 weeks&#xD;
&#xD;
         14. Have a history of anaphylaxis or other serious adverse reactions to vaccines&#xD;
&#xD;
         15. Have previously received an HIV vaccine&#xD;
&#xD;
         16. Volunteers with any of the following laboratory parameters at the screening visit&#xD;
             (within 30 days of immunization): Hemoglobin &lt;10 (without having received a blood or&#xD;
             red blood cell transfusion within 30 days prior to laboratory test); neutrophil count&#xD;
             &lt;750 cells/mm3; platelet count &lt;50,000/mm3; serum creatinine &gt; 2.0 mg/dL; aspartate&#xD;
             aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 times the upper limits of&#xD;
             normal; total bilirubin &gt; 1.5 mg/dL&#xD;
&#xD;
         17. Pregnant women or women who are breast-feeding; female volunteers of childbearing&#xD;
             potential who are not using or willing to use an effective (as judged by the&#xD;
             investigator) barrier contraceptive methods or abstinence while enrolled in this&#xD;
             study.&#xD;
&#xD;
         18. Use of any immune modulators or suppressors within 45 days of study entry including&#xD;
             but not limited to agents such as interleukins (e.g. IL-2), interferons (e.g. IFN-*),&#xD;
             high dose systemic steroids (e.g. â‰¥ 20 mg prednisone equivalent/day) for &gt; 30 days,&#xD;
             thalidomide, filgrastim (G-CSF), sargramostim (GM-CSF), dinitrochlorobenzene (DNCB),&#xD;
             thymosin alpha, thymopentin, inosiplex, polyribonucleoside, ditiocarb sodium,&#xD;
             cyclosporin, mycophenolate mofetil, methotrexate, and cancer chemotherapy.&#xD;
&#xD;
         19. No other investigational agent within 30 days of study entry&#xD;
&#xD;
         20. Any other condition which, in the opinion of the investigator, might interfere with&#xD;
             completion of the study or evaluation of the results&#xD;
&#xD;
         21. Have active Hepatitis B virus infection (positive HBsAg) or Hepatitis C&#xD;
             infection(defined as positive antibodies)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles E Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Human Virology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Institute of Human Virology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <results_first_submitted>January 2, 2019</results_first_submitted>
  <results_first_submitted_qc>October 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2021</results_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Mohammad Sajadi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>healthy volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02756208/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02756208/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>300 ug FLSC Vaccine</title>
          <description>Highest dose vaccine group</description>
        </group>
        <group group_id="P2">
          <title>150 ug FLSC Vaccine</title>
          <description>Middle dose vaccine group</description>
        </group>
        <group group_id="P3">
          <title>75 ug FLSC Vaccine</title>
          <description>Lowest dose vaccine group</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat Analysis: Subjects who received at least 1 dose of vaccine or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>300 ug FLSC Vaccine</title>
          <description>Highest dose vaccine group</description>
        </group>
        <group group_id="B2">
          <title>150 ug FLSC Vaccine</title>
          <description>Middle dose vaccine group</description>
        </group>
        <group group_id="B3">
          <title>75 ug FLSC Vaccine</title>
          <description>Lowest dose vaccine group</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo control group</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="8.8"/>
                    <measurement group_id="B2" value="33.3" spread="7.2"/>
                    <measurement group_id="B3" value="36.5" spread="5.5"/>
                    <measurement group_id="B4" value="32.2" spread="7.5"/>
                    <measurement group_id="B5" value="33.4" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local and Systemic Reactogenicity Signs and Symptoms</title>
        <description>Signs and symptoms include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms.</description>
        <time_frame>48 weeks</time_frame>
        <population>Intention-to-treat Population - All subjects who received at least one dose of vaccine/placebo</population>
        <group_list>
          <group group_id="O1">
            <title>300 ug FLSC Vaccine</title>
            <description>Highest dose vaccine group</description>
          </group>
          <group group_id="O2">
            <title>150 ug FLSC Vaccine</title>
            <description>Middle dose vaccine group</description>
          </group>
          <group group_id="O3">
            <title>75 ug FLSC Vaccine</title>
            <description>Lowest dose vaccine group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo control group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Reactogenicity Signs and Symptoms</title>
          <description>Signs and symptoms include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms.</description>
          <population>Intention-to-treat Population - All subjects who received at least one dose of vaccine/placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Related Adverse Events</title>
        <description>Treatment emergent adverse events assessed by investigator to be either possibly, probably, or definitely related to study treatment. Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products.</description>
        <time_frame>48 weeks</time_frame>
        <population>Intention-to-treat population: Subjects who have received at least one dose of vaccine/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>300 ug FLSC Vaccine</title>
            <description>Highest dose vaccine group</description>
          </group>
          <group group_id="O2">
            <title>150 ug FLSC Vaccine</title>
            <description>Middle dose vaccine group</description>
          </group>
          <group group_id="O3">
            <title>75 ug FLSC Vaccine</title>
            <description>Lowest dose vaccine group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo control group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Adverse Events</title>
          <description>Treatment emergent adverse events assessed by investigator to be either possibly, probably, or definitely related to study treatment. Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products.</description>
          <population>Intention-to-treat population: Subjects who have received at least one dose of vaccine/placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Decrease in CD4 Count and CD4%.</title>
        <description>CD4 count was monitored from baseline and at each study visit through study completion. Baseline CD4 and CD4% levels were calculated by taking the average of the screening and first vaccination visits. The number of individuals who had sustained (2 consecutive time points) 30% decrease in CD4 cell/ul and CD4% from baseline were counted.</description>
        <time_frame>48 weeks</time_frame>
        <population>The analysis included number of participants with sustained (2 consecutive time points) of 30% decrease in CD4 cell/ul and CD4%.</population>
        <group_list>
          <group group_id="O1">
            <title>300 ug FLSC Vaccine</title>
            <description>Highest dose vaccine group</description>
          </group>
          <group group_id="O2">
            <title>150 ug FLSC Vaccine</title>
            <description>Middle dose vaccine group</description>
          </group>
          <group group_id="O3">
            <title>75 ug FLSC Vaccine</title>
            <description>Lowest dose vaccine group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo control group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Decrease in CD4 Count and CD4%.</title>
          <description>CD4 count was monitored from baseline and at each study visit through study completion. Baseline CD4 and CD4% levels were calculated by taking the average of the screening and first vaccination visits. The number of individuals who had sustained (2 consecutive time points) 30% decrease in CD4 cell/ul and CD4% from baseline were counted.</description>
          <population>The analysis included number of participants with sustained (2 consecutive time points) of 30% decrease in CD4 cell/ul and CD4%.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Binding Antibody Response Rates to FLSC</title>
        <description>Percent of participants with anti-FLSC antibodies as assessed by ELISA by 2 weeks after final vaccination</description>
        <time_frame>2 weeks after 4th (last) vaccination.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300 ug FLSC Vaccine</title>
            <description>Highest dose vaccine group</description>
          </group>
          <group group_id="O2">
            <title>150 ug FLSC Vaccine</title>
            <description>Middle dose vaccine group</description>
          </group>
          <group group_id="O3">
            <title>75 ug FLSC Vaccine</title>
            <description>Lowest dose vaccine group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo control group</description>
          </group>
        </group_list>
        <measure>
          <title>Binding Antibody Response Rates to FLSC</title>
          <description>Percent of participants with anti-FLSC antibodies as assessed by ELISA by 2 weeks after final vaccination</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Binding Antibody Response Rates to BaL-gp120</title>
        <description>Percent of participants with anti-gp120 antibodies as assessed by ELISA</description>
        <time_frame>2 weeks after 4th (last) vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300 ug FLSC Vaccine</title>
            <description>Highest dose vaccine group</description>
          </group>
          <group group_id="O2">
            <title>150 ug FLSC Vaccine</title>
            <description>Middle dose vaccine group</description>
          </group>
          <group group_id="O3">
            <title>75 ug FLSC Vaccine</title>
            <description>Lowest dose vaccine group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo control group</description>
          </group>
        </group_list>
        <measure>
          <title>Binding Antibody Response Rates to BaL-gp120</title>
          <description>Percent of participants with anti-gp120 antibodies as assessed by ELISA</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Competitive Antibody Rates to CD4i Epitopes</title>
        <description>Percent of participants with antibodies competing with A32 or 17b as assessed by ELISA.</description>
        <time_frame>2 weeks after 4th (last) vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300 ug FLSC Vaccine</title>
            <description>Highest dose vaccine group</description>
          </group>
          <group group_id="O2">
            <title>150 ug FLSC Vaccine</title>
            <description>Middle dose vaccine group</description>
          </group>
          <group group_id="O3">
            <title>75 ug FLSC Vaccine</title>
            <description>Lowest dose vaccine group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo control group</description>
          </group>
        </group_list>
        <measure>
          <title>Competitive Antibody Rates to CD4i Epitopes</title>
          <description>Percent of participants with antibodies competing with A32 or 17b as assessed by ELISA.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>300 ug FLSC Vaccine</title>
          <description>Highest dose vaccine group</description>
        </group>
        <group group_id="E2">
          <title>150 ug FLSC Vaccine</title>
          <description>Middle dose vaccine group</description>
        </group>
        <group group_id="E3">
          <title>75 ug FLSC Vaccine</title>
          <description>Lowest dose vaccine group</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Control group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Acute cholecystitis requiring hospitalization and surgery</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Substance abuse</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Substance abuse relapse resulting in hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Depression resulting in hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <description>Suicidal ideation resulting in hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <description>Alcohol withdrawal syndrome resulting in hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mohammad Sajadi</name_or_title>
      <organization>Institute of Human Virology</organization>
      <phone>410-7061779</phone>
      <email>msajadi@ihv.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

